Bedrock

Bedrock Therapeutics is a pre-clinical stage biotechnology company specializing in the development of next-generation adeno-associated virus (AAV) gene therapies. The company's core technology focuses on engineering human-tropic and antibody-evading AAV capsids designed to improve delivery efficiency and bypass pre-existing immunity. Their lead program, BDRK-401, utilizes single-chain immune modulators (scIMs) to prevent corneal transplant rejection by shielding donor tissue from the host's immune response. Beyond ophthalmology, Bedrock is exploring applications in hemophilia, solid organ transplantation, and autoimmune diseases like Type 1 diabetes. The company is headquartered in Raleigh, North Carolina, and was founded by experts in AAV vectorology and ocular medicine from UNC Chapel Hill and NC State.